As the US Supreme Court mulls the so-called pay-for-delay schemes of the pharmaceutical industry, major drugstore retail chain Walgreen Co. has reportedly acquired a majority ownership stake of a pharmaceutical wholesaler, giving Walgreens a major upper-hand when negotiating drug prices. Walgreens currently has a supply agreement with AmerisourceBergen Corp. in a 10-year deal. Now, Walgreens will hold a majority stake in the company, while European retailer Alliance Boots will hold a minority stake. The contract allows Walgreens and Boots to buy up to 7 percent of AmerisouceBergen’s shares as well as warrants to pursue another 16 percent. The deal is just a further expansion of Walgreen’s $7 billion investment in global expansion; if Walgreens pursues its ability to purchase another 16 percent in 2015, the chain will have fully acquired AmerisourceBergen. The pharmaceutical wholesaler supplies brand name and generic drugs to Walgreens.
Featured News
White House Prepares Overhaul of U.S. Cyber Rules
Dec 16, 2025 by
CPI
DirecTV Wins Second Chance in Antitrust Case Against Nexstar
Dec 16, 2025 by
CPI
Democrats Call for Tough Review of Nexstar-Tegna Merger
Dec 16, 2025 by
CPI
US FTC and States Expand Suit Accusing Uber of Deceptive Subscription Practices
Dec 16, 2025 by
CPI
US Hits Pause on Implementing UK Trade Deal Amid Disagreement on Digital Regs
Dec 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi